EU's CHMP snubs Janssen-Cilag's Zeftera appeal
This article was originally published in Scrip
Executive Summary
The EU's CHMP has confirmed its negative opinion of Basilea Pharmaceutica's broad-spectrum antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and soft tissue infections (cSSTI), following an appeal by Janssen-Cilag (Johnson & Johnson), which used to own exclusive worldwide rights to the product.